MarsLight-11

Beyond's analysis on MarsLight-11

• 2026-09-28 — Innovent broadens its Phase 3 NSCLC trial to non‑squamous patients, expanding the potential patient base for its IL‑2/PD‑1 bispecific

Recent news mentioning MarsLight-11

• 2026-09-28 — Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

Appears alongside

• NSCLC

Browse the full archive →